This activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding the role of pan-tumor HER2 testing in advanced solid cancers. HER2 overexpression by IHC is a predictive biomarker for response to a HER2-directed antibody drug conjugate (ADC) in patients with advanced solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
Provided by the American Society for Clinical Pathology in partnership with Q Synthesis LLC.
Activity Agenda
-
Review of recent updates in pan-tumor HER2 testing and targeted therapy
-
HER2 testing in advanced solid tumors
-
Practical considerations for the laboratory
Target Audience
This activity has been designed to meet the educational needs of pathologists, laboratory professionals, and other members of the cancer care team.
Learning Objectives
Upon completion of this activity, you will be able to:
-
Identify when HER2 testing may be indicated in patients with advanced solid tumors
-
Describe how the use of certain HER2-directed therapy may impact clinical outcomes in patients with advanced solid tumors based on HER testing results
-
Outline how HER2 testing may be performed in different types of advanced solid tumors
Faculty
Joseph Kim, MD, MPH, MBA
President, Q Synthesis LLC
Faculty Disclosures
Dr. Kim has no financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of .5 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of .5 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must attend the program. CME certificates will be provided on-line.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.